Investing in biotech stocks isn't for everyone. An unsuccessful clinical trial can cause a huge decline. The competition is ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Three Motley Fool contributors think they've identified dirt-cheap healthcare stocks to buy right now. Here's why they picked ...

Vertex Pharmaceuticals Inc. closed $45.72 below its 52-week high ($510.64), which the company achieved on August 1st.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...

CRISPR stock skyrocketed to $199 in 2021, but has since fallen 74% to its current price of $50. This gives the firm a $4.3bn ...

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

This was the stock's second consecutive day of losses.

According to Benzinga Pro, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.15%, ...

Barclays has recently reduced Vertex Pharmaceuticals Incorporated (VRTX) stock to Equal Weight rating, as announced on August 5, 2024, according to Finviz. Earlier, on June 27, 2024, Redburn Atlantic ...

Analysts at Precedence Research expect the gene-editing market to grow 15.7% annually and reach $29.9 billion by 2032, ...